Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The cancer premium - explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland: a cross sectional study.
EClinicalMedicine
July 2023
Institute of Law, University of Zurich, Switzerland.
Background: High treatment prices of new cancer drugs are a global public health challenge to patients and healthcare systems. Policymakers in the US and Europe are debating reforms to drug pricing. The objective of this study was to assess whether drug efficacy or epidemiological characteristics (prevalence, incidence, mortality) explain the gap in treatment prices between cancer and non-cancer drugs in the US, Germany, and Switzerland.
View Article and Find Full Text PDFMedication Adherence Evaluated Through Electronic Monitors During the 2020 COVID-19 Pandemic Lockdown in Switzerland: A Longitudinal Analysis.
Patient Prefer Adherence
August 2022
School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Background: During the 2020 COVID-19 lockdown, patients included in the Interprofessional Medication Adherence Program (IMAP) in Switzerland continued to use electronic monitors (EMs) that registered daily drug-dose intake. We aimed to understand to what extent patients' medication implementation (ie, the extent to which the patient took the prescribed medicine), measured with EMs, was impacted by the lockdown.
Methods: Patients participating in the IMAP were diagnosed with diabetic kidney disease (DKD), solid cancer, human immunodeficiency virus (HIV) and miscellaneous long-term diseases (MLTD).
Prevalence and factors associated with chronic use of levothyroxine: A cohort study.
PLoS One
January 2022
Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Importance: Levothyroxine prescriptions are rising worldwide. However, there are few data on factors associated with chronic use.
Objective: To assess the prevalence of chronic levothyroxine use, its rank among other chronic drugs and factors associated with chronic use.
Influence of Prednisone on Inflammatory Biomarkers in Community-Acquired Pneumonia: Secondary Analysis of a Randomized Trial.
J Clin Pharmacol
November 2021
Department of General Internal and Emergency Medicine and Department of Endocrinology, Diabetology and Metabolism, Medical University Clinic, Aarau, Switzerland.
Article Synopsis
- Glucocorticoids, like prednisone, are widely used for treating inflammation and have gained attention for their potential role in COVID-19 treatment.
- A study involving 711 hospitalized patients with pneumonia compared the effects of 50-mg prednisone over 7 days versus placebo, focusing on inflammatory markers.
- Results showed that prednisone reduced C-reactive protein (CRP) levels significantly while increasing leukocyte and neutrophil counts, with procalcitonin (PCT) levels unchanged, suggesting PCT may better indicate infection resolution than traditional markers.
Antibiotic prescription monitoring and feedback in primary care in Switzerland: Design and rationale of a nationwide pragmatic randomized controlled trial.
Contemp Clin Trials Commun
March 2021
Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Introduction: Antibiotic consumption is highest in primary care, and antibiotic overuse furthers antimicrobial resistance. In our recently published pilot-RCT, we used monthly aggregated claims data to provide personalized antibiotic prescription feedback to general practitioners (GPs). The pilot-RCT has shown that personalized prescription feedback is a feasible and promising low-cost intervention to reduce antibiotic prescribing.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!